Viral Vector Market by Type (Adenoviral Vectors, Lentiviral Vectors, Retroviral Vectors, Adeno-associated Viral Vectors, Others); by Disease (Genetic Disorders, Infectious Diseases, Cancer, Others); by Application (Basic Research, Vaccinology, Gene Therapy); by Region (North America, Europe, Asia-Pacific, Latin America. Middle East and Africa): Global Forecasts 2021 To 2027

The Global Viral Vector Market size was valued at USD 451.0 Mn by 2020 and is expected to reach USD 1,564.4 Mn by 2027, with a growing CAGR of 20% during the forecast period.

Viral Vector Market Definition

Viral vector is a tool which is used by molecular biologists to deliver important instructions or genetic material to the targeted cells. Viral vectors have specialized molecular mechanisms that transport genetic material inside the cells they infect. Viral vectors are highly used in gene therapy and vaccine development, as it has high specific delivery of genes to target cells, increase cellular immunity and have high-efficiency gene transduction.

Viral Vector Market

Viral Vector Market Dynamics

The driving factors influencing the global viral vector market include growing advances in genetic technology and rising incidences of chronic diseases such as genetic disorders such as down syndrome, Huntington’s syndrome, and cystic syndrome. Moreover, increase funding in research and development activities in genetic therapy is expected to boost the growth of viral vector industry. In addition to this, growing investments into biopharmaceutical productions and rise in government spending on research leverage the growth of viral vector industry.

Increasing healthcare spending and adoption of gene therapy in the treatment is expected to thrive the demand for viral vector industry during the forecast period. Gendicine is the first gene therapy product approved for clinical use in humans in 2003. Gendicine is manufactured by SiBiono GeneTech which was indicated for head and neck squamous cell carcinoma. Such gene therapy product approvals create opportunities for key market players and boost the growth of viral vector industry.

 Global Viral Vector Market Segmentation:

By Type

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Adeno-associated Viral Vectors
  • Others

By Diseases

  • Genetic Disorders
  • Infectious Diseases
  • Cancer
  • Others

By Applications

  • Basic Research
  • Vaccinology
  • Gene Therapy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Based on type, adeno-associated viral vectors segment accounted for maximum market share in 2020 due to increase its application in treatment of genetic diseases

Based on type, viral vector market is segmented into adenoviral vectors, lentiviral vectors, retroviral vectors and adeno-associated viral vectors. Adeno-associated viral vector is expected to hold the largest market share during forecast period due to its advances in targeting wide range of cells and tissue for gene therapy. The major advantage of AAV (Adeno-Associated Virus) is its long-term expression for transgenes. This offers benefits for the scientists, which can be used as tool in gene therapy. This leverages the demand for adeno-associated viral vector in genetics.

For instance, on February 2021, Biotech Entrepreneur George Chruch launched the latest gene therapy start-up to design safer viral vector which is AAVs immune surveillance obtained by inhibiting the activation of DNA-sensing protein called Toll-like receptor-9 (TLR9). This invention is expected to reduce inflammation and T-cell responses by improving gene expression. Such ongoing inventions on adeno-associated viral vector is expected to boost the growth of viral vector industry.

Based on disease, cancer segment is expected to dominate the market during forecast period owing to rise in prevalence of cancer disease

Based on disease, viral vector market is broadly segmented into genetic disorders, infectious diseases, and cancer. Cancer disease is anticipated to witness fastest growth with highest CAGR during forecast period due to ongoing research activities on cancer. Moreover, increase in number of cancer patients, growing application of viral vector in cancer treatments and rising demand for target specific therapy are expected to boost the growth of market.

According to National Clinical Trial Registry-2021, more than 95 ongoing interventional clinical trials related to the gene therapy for distinct phases of cancer. The upsurge adoption of modern healthcare facilities and therapies is expected to uplift the growth of viral vector industry.

Based on applications, gene therapy held the largest market share in 2020 and is expected to increase more during forecast period due to growing research activities in genetics

Based on applications, viral vector market is broadly segmented into basic research, vaccinology, and gene therapy. Gene therapy accounted for highest market share in 2020 due its promising therapy effect in treating various diseases such as cancer, diabetes, AIDS, heart diseases and cystic fibrosis. Moreover, ongoing research into viral vector gene therapies and growing product approvals for viral vector is expected to thrive the growth of market.

For instance, in 2020, VBL Therapeutics developed VB-111 for targeted anti-cancer gene therapy agent. Moreover, VB-111 is currently being evaluated in phase 3 clinical trial for the treatment of platinum-resistant ovarian cancer. Such inventions leverage the growth of market.

Based on geographical region, North America dominated the market in 2020 owing to high adoption of gene therapy

Based on region, North America is expected to dominate the market during forecast period owing to rise in genetic disorders and increase in genomic–based research activities. According to the survey, the US undertook around 67% of gene therapy clinical trials, however, other countries such as UK, Germany, and Switzerland, China, & Japan contribute 10%, 4% and 3% respectively. Growing research and inventions in viral vector therapy is expected to boost the growth of viral vector industry.

Company Profiles and Competitive Intelligence

The key players operating in the viral vector market are:

  • Lonza
  • Merck
  • Oxford BioMedica
  • CGT Catapult
  • Cobra Biologics
  • uniQure
  • FUJIFILM Diosynth Biotechnologies
  • Spark Therapeutics
  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • FinVector Oy
  • Genelux Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • MaxCyte, Inc
  • Sirion-Biotech GmbH Spark Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vector Biolabs
  • Vigene Biosciences, Inc.
  • Virovek, Inc

The report also provides an in-depth analysis of viral vector market dynamics such as drivers, restraints, opportunities, and challenges


  • Growing aging population
  • Increase in demand for targeted therapy for site-specific diseases
  • Rising incidences for chronic diseases such as genetic diseases
  • Increasing government spending on genetic-based research


  • Stringent regulatory policies for product approvals
  • Inflated cost of treatments and products


  • Emergence of key market players
  • Health decentralization and exploration of untapped region across the globe


  • Random insertion of genome into the host that will cause activation of oncogene inside the body
  • Short life of viral vectors

COVID-19 Impact on the Viral Vector Market Analysis

Covid-19 has positively impacted the growth of viral vector industry. Increase in applications of viral vectors in development of vaccine has boosted the growth of industry in the recent past. Development of covid-19 vaccine has benefited people by providing protection against covid-19 infection across the globe.

Pharmaceutical and biopharmaceutical companies focused on the research and development of viral vector-based vaccine to meet the rising demand of the globe. Johnson & Johnson, Janssen developed a viral vector vaccine to treat covid-19 infected patients which was authorized for emergency use in the US. Such upsurge in the development of viral vector vaccines for covid-19 infection is expected to uplift the growth of viral vector market during the forecast period.

The report also provides an in-depth analysis of key trends in the viral vector market

  • Increase in application of gene therapy in the treatment of wide variety of inherited and acquired diseases
  • Viral vector-based cancer therapy is the emerging application of naturally and engineered occurring oncolytic viral vectors

The report also provides an in-depth analysis of recent news developments and investments

  • In March 2021, Albumedix collaborated with Cobra Biologics for the upstream & downstream processing of lentiviral and AAV vector for the development of gene therapy for genetic disorders. This collaboration aimed for process optimization and stability enhancement in development of product.
  • In November 2020, Vibalogics invested $150 Mn to build 110,000 sq-foot manufacturing facility near Boston in US. This facility would be used for clinical and commercial-stage product development for oncolytic viruses and viral vectors. This development will help to expand the business of the company.

The unique insights provided by this report also includes the following:

  • In-depth Value Chain Analysis
  • Opportunity Mapping
  • Sector Snapshot
  • Key Players Positioning Matrix
  • Regulatory Scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market Trends
  • Covid-19 Impact Analysis
  • Product Comparison
  • Pre & Post COVID 19 Impacts on Viral Vector Market
  • Competitive Landscape

Frequently Asked Questions (FAQs)

The global market was valued at USD 451 Mn in 2020 and is anticipated to reach USD 1564.4 Mn by 2027.

The global market is estimated to grow at a compound annual growth rate (CAGR) of 20% during forecast period.

In the base year 2020, North America held the largest share in the market.

Stringent regulatory policies for product approvals is expected to restraint the growth of market.

As per expert opinions, increase in chronic diseases genetic diseases, growing application of gene therapy and rising research activities in viral vector will drive the growth market.

Few key players include, but not limit up to: Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, uniQure, FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Batavia Biosciences B.V., and BioNTech IMFS GmbH among other players.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

  1.  Introduction
    1. Product Outline
    2. What is Viral Vector?
    3. Analysis of Viral Vector Market
    4. COVID -19 Impact
    5. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
  2. Regulatory Landscape for Viral Vector Market
    1. Regulations and Standards
  3. Viral Vector Market by Type
    1. Adenoviral Vectors
    2. Lentiviral Vectors
    3. Retroviral Vectors
    4. Adeno-associated Viral Vectors
    5. Others
  4. Viral Vector Market by Diseases
    1. Genetic Disorders
    2. Infectious Diseases
    3.  Cancer
    4.  Others
  5. Viral Vector Market by Applications
    1. Basic Research
    2. Vaccinology
    3. Gene Therapy
  6. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France 
      4. Spain
      5. Italy
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Australia
      5. Rest Of Asia Pacific
    4. Latin America
      1. Brazil
      2. Mexico
      3. Rest of the Latin America
    5. Middle East and Africa
      1. South Africa
      2. Rest of the Middle East and Africa
  7. Key Strategic Insights
  8. Market Analysis
    1. Opportunity Mapping
    2. Critical Success Factors
    3. Consumer Preferences
  9.  Key Market Trends / Recent Developments
  10. Competitive Scenario
    1. Mergers and Acquisitions
    2. Investments
    3. Joint Ventures
    4. New Product Launches
    5. Ranking of Key Players
  11. Key Global Players
    1. Lonza
    2. Merck
    3. Oxford BioMedica
    4. CGT Catapult
    5. Cobra Biologics
    6. uniQure
    7. FUJIFILM Diosynth Biotechnologies
    8. Spark Therapeutics
    9. Batavia Biosciences B.V.
    10. BioNTech IMFS GmbH
    11. FinVector Oy
    12. Genelux Corporation
    13. Kaneka Eurogentec S.A.
    14. Lonza Group AG
    15. MaxCyte, Inc
    16. Others

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization